The 10-second takeaway
For the quarter ended June 30 (Q2), MAKO Surgical met expectations on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly and GAAP loss per share dropped.
Margins grew across the board.
MAKO Surgical reported revenue of $23.7 million. The nine analysts polled by S&P Capital IQ expected a top line of $23.7 million on the same basis. GAAP reported sales were 27% higher than the prior-year quarter's $18.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.20. The eight earnings estimates compiled by S&P Capital IQ predicted -$0.22 per share. GAAP EPS were -$0.20 for Q2 compared to -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 73.1%, 260 basis points better than the prior-year quarter. Operating margin was -35.9%, 1,810 basis points better than the prior-year quarter. Net margin was -36.1%, 1,720 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $27.8 million. On the bottom line, the average EPS estimate is -$0.16.
Next year's average estimate for revenue is $109.0 million. The average EPS estimate is -$0.78.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 1,135 members out of 1,175 rating the stock outperform, and 40 members rating it underperform. Among 247 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 233 give MAKO Surgical a green thumbs-up, and 14 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MAKO Surgical is hold, with an average price target of $34.57.
The healthcare investing landscape is littered with also-rans and a few major winners. Is MAKO Surgical the right stock for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will be a phenomenal success over the next few years. Click here for instant access to this free report.
- Add MAKO Surgical to My Watchlist.